+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals



Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals



Expert Review of Molecular Diagnostics 15(7): 869-880



Companion diagnostics are essential for the safe and effective use of the corresponding therapeutic products. The US FDA has approved a number of companion diagnostics used to select cancer patients for treatment with contemporaneously approved novel therapeutics. The processes of co-development and co-approval of a therapeutic product and its companion diagnostic have been a learning experience that continues to evolve. Using several companion diagnostics as examples, this article describes the challenges associated with the scientific, clinical and regulatory hurdles faced by FDA and industry alike. Taken together, this discussion is intended to assist manufacturers toward a successful companion diagnostics development plan.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057454287

Download citation: RISBibTeXText

PMID: 26109316

DOI: 10.1586/14737159.2015.1045490


Related references

Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer. Journal of Personalized Medicine 6(1):, 2016

Drug approvals 2011: focus on companion diagnostics. Journal of the National Cancer Institute 104(2): 84-86, 2012

Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan. Breast Cancer 23(1): 19-23, 2016

Intellectual property considerations for molecular diagnostic development with emphasis on companion diagnostics. Expert Opinion on Therapeutic Patents 28(2): 123-128, 2018

Advances in companion animal medicine and surgery. Papers from a meeting on "Regulatory Peptides and Diseases of Companion Animals". September 10-12, 1986, Utrecht. Veterinary Quarterly 9(3): 235-286, 1987

The impact of new trends in POCTs for companion diagnostics, non-invasive testing and molecular diagnostics. Expert Review of Molecular Diagnostics 15(6): 815-827, 2015

The Regulation of Companion Diagnostics: A Global Perspective. Therapeutic Innovation and Regulatory Science 47(4): 405-415, 2013

FDA perspective on companion diagnostics: an evolving paradigm. Clinical Cancer Research 20(6): 1453-1457, 2014

The Regulation of Companion Diagnostics A Global Perspective. Therapeutic Innovation & Regulatory Science 47(4): 405-415, 2013

Companion and Complementary Diagnostics: Clinical and Regulatory Perspectives. Trends in Cancer 2(12): 706-712, 2016

Personalized medicine, pharmacogenomics, and companion diagnostics. Current and future applications of molecular diagnostics will influence these emerging fields. Mlo: Medical Laboratory Observer 47(2): 22-23, 2015

Current Trends in Personalized Medicine and Companion Diagnostics: A Summary From the DIA Meeting on Personalized Medicine and Companion Diagnostics. Therapeutic Innovation and Regulatory Science 49(4): 530-543, 2015

Companion diagnostics for targeted cancer drugs - clinical and regulatory aspects. Frontiers in Oncology 4: 105, 2014

Overcoming regulatory challenges in the development of companion diagnostics for monitoring and safety. Personalized Medicine 13(2): 155-167, 2016

Companion Diagnostics and the Drug–Diagnostic Codevelopment Model. Drug Development Research 73(7), 2012